Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides

Aeglea BioTherapeutics · 2023-03
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

39
every slide · same image gating as the playbook
01
Slide 1
Includes company logo, tagline, date, and ticker symbol.front_matter
03
The slide uses a split-screen layout with a photo on the left and text on a dark blue background on the right.inspire_vision
Open slide detailLoop · Golden Circle
04
inspire_vision
Open slide detailLoop · Golden Circle
05
The slide uses a Gantt-style chart to represent clinical trial progress for three distinct programs.plan_implementation
Open slide detailLoop · Golden Circle
06
show_traction
07
front_matter
08
frame_problem
Open slide detailBeat · Problem
09
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the difficulty of treatment compliance.frame_problem
Open slide detailBeat · Problem
10
The slide uses a pie chart for segmentation and a timeline/number line for diagnostic age, followed by key clinical metrics.size_opportunity
Open slide detailBeat · AgitateLoop · Mece Breakdown
11
Includes a biological process diagram showing intracellular vs plasma metabolism.present_solution
Open slide detailBeat · SolutionLoop · Mece Breakdown
12
The chart shows a clear dose-response relationship between 1.0 mg/kg and 10.0 mg/kg doses, with statistical significance marked at early time points.show_traction
Open slide detailBeat · Solution
13
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to demonstrate drug efficacy.show_traction
Open slide detailBeat · Solution
14
The slide outlines a two-part clinical trial structure with specific cohorts and patient criteria.plan_implementation
Open slide detailBeat · Solution
15
summarize
Open slide detailBeat · Solution
16
front_matter
17
Includes a timeline-based progression of symptoms from infancy to adulthood.frame_problem
18
establish_context
19
Includes statistical significance markers and clinical guideline thresholds.show_traction
20
Includes statistical significance (p-values) and MCID reference lines for GMFM-E.show_traction
21
The slide uses a heatmap to visualize individual patient outcomes, a common technique in clinical trial reporting.show_traction
22
Data presented as n (%).analyze_data
23
plan_implementation
24
transition
25
show_traction
Open slide detailBeat · Impact and Next Steps
26
Includes footnotes detailing cash equivalents and share breakdown.analyze_data
Open slide detailBeat · Impact and Next Steps
27
front_matter
28
The slide uses a process flow diagram to contrast intracellular metabolism with plasma-based enzymatic intervention.present_solution
29
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.frame_problem
Open slide detailLoop · Cost Of Inaction
30
Includes histological images of liver tissue and a dot plot showing BMD improvement.show_traction
Open slide detailLoop · Cost Of Inaction
31
Clinical trial baseline data table.analyze_data
32
The table displays mean/SD and median/range for continuous variables, and counts/percentages for categorical variables.analyze_data
33
The slide uses a box plot to visualize longitudinal clinical trial data.show_traction
34
Includes both continuous mean change data and categorical responder analysis.show_traction
35
Includes a study design timeline and clinical endpoint data tables/charts.analyze_data
36
The slide uses standard clinical metrics for motor function assessment.establish_context
37
The slide uses a process flow diagram to illustrate the clinical trial structure.plan_implementation
38
The table highlights specific clinical improvements for six individual patients, emphasizing normalization of mobility.show_traction
39
The slide uses a split-screen layout: left side is market sizing/segmentation, right side is a 2x2 strategic framework for launch execution.plan_implementation